Ensuring Patient Access to Critical Breakthrough Products Act
House: Reported
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3.
Sign in to view Hilltelligence’s plain-English summary.
Action Timeline
- HouseLatest
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3.
- House
Committee Consideration and Mark-up Session Held
- House
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- House
Introduced in House
Sign in to view Hilltelligence’s passage-probability analysis.
Official Sources
Topics
Policy area
Legislative subjects
Congressional oversightDrug safety, medical device, and laboratory regulationHealth care costs and insuranceHealth care coverage and accessHealth programs administration and fundingHealth technology, devices, suppliesMedicare
Sign in to view Hilltelligence’s potential-cosponsor analysis.